These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 21552327)

  • 1. PTG depletion removes Lafora bodies and rescues the fatal epilepsy of Lafora disease.
    Turnbull J; DePaoli-Roach AA; Zhao X; Cortez MA; Pencea N; Tiberia E; Piliguian M; Roach PJ; Wang P; Ackerley CA; Minassian BA
    PLoS Genet; 2011 Apr; 7(4):e1002037. PubMed ID: 21552327
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glycogen synthase downregulation rescues the amylopectinosis of murine RBCK1 deficiency.
    Nitschke S; Sullivan MA; Mitra S; Marchioni CR; Lee JPY; Smith BH; Ahonen S; Wu J; Chown EE; Wang P; Petković S; Zhao X; DiGiovanni LF; Perri AM; Israelian L; Grossman TR; Kordasiewicz H; Vilaplana F; Iwai K; Nitschke F; Minassian BA
    Brain; 2022 Jul; 145(7):2361-2377. PubMed ID: 35084461
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PTG protein depletion rescues malin-deficient Lafora disease in mouse.
    Turnbull J; Epp JR; Goldsmith D; Zhao X; Pencea N; Wang P; Frankland PW; Ackerley CA; Minassian BA
    Ann Neurol; 2014 Mar; 75(3):442-6. PubMed ID: 24419970
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting Gys1 with AAV-SaCas9 Decreases Pathogenic Polyglucosan Bodies and Neuroinflammation in Adult Polyglucosan Body and Lafora Disease Mouse Models.
    Gumusgoz E; Guisso DR; Kasiri S; Wu J; Dear M; Verhalen B; Nitschke S; Mitra S; Nitschke F; Minassian BA
    Neurotherapeutics; 2021 Apr; 18(2):1414-1425. PubMed ID: 33830476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glycogen hyperphosphorylation underlies lafora body formation.
    Turnbull J; Wang P; Girard JM; Ruggieri A; Wang TJ; Draginov AG; Kameka AP; Pencea N; Zhao X; Ackerley CA; Minassian BA
    Ann Neurol; 2010 Dec; 68(6):925-33. PubMed ID: 21077101
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Laforin preferentially binds the neurotoxic starch-like polyglucosans, which form in its absence in progressive myoclonus epilepsy.
    Chan EM; Ackerley CA; Lohi H; Ianzano L; Cortez MA; Shannon P; Scherer SW; Minassian BA
    Hum Mol Genet; 2004 Jun; 13(11):1117-29. PubMed ID: 15102711
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advances in lafora progressive myoclonus epilepsy.
    Delgado-Escueta AV
    Curr Neurol Neurosci Rep; 2007 Sep; 7(5):428-33. PubMed ID: 17764634
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Laforin prevents stress-induced polyglucosan body formation and Lafora disease progression in neurons.
    Wang Y; Ma K; Wang P; Baba O; Zhang H; Parent JM; Zheng P; Liu Y; Minassian BA; Liu Y
    Mol Neurobiol; 2013 Aug; 48(1):49-61. PubMed ID: 23546741
    [TBL] [Abstract][Full Text] [Related]  

  • 9. AAV-Mediated Artificial miRNA Reduces Pathogenic Polyglucosan Bodies and Neuroinflammation in Adult Polyglucosan Body and Lafora Disease Mouse Models.
    Gumusgoz E; Kasiri S; Guisso DR; Wu J; Dear M; Verhalen B; Minassian BA
    Neurotherapeutics; 2022 Apr; 19(3):982-993. PubMed ID: 35347645
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polyglucosan body structure in Lafora disease.
    Brewer MK; Putaux JL; Rondon A; Uittenbogaard A; Sullivan MA; Gentry MS
    Carbohydr Polym; 2020 Jul; 240():116260. PubMed ID: 32475552
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neurodegeneration and functional impairments associated with glycogen synthase accumulation in a mouse model of Lafora disease.
    Valles-Ortega J; Duran J; Garcia-Rocha M; Bosch C; Saez I; Pujadas L; Serafin A; Cañas X; Soriano E; Delgado-García JM; Gruart A; Guinovart JJ
    EMBO Mol Med; 2011 Nov; 3(11):667-81. PubMed ID: 21882344
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Accumulation of Laforin and Other Related Proteins in Canine Lafora Disease With EPM2B Repeat Expansion.
    Chambers JK; Thongtharb A; Shiga T; Azakami D; Saito M; Sato M; Morozumi M; Nakayama H; Uchida K
    Vet Pathol; 2018 Jul; 55(4):543-551. PubMed ID: 29444631
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progressive myoclonus epilepsy with polyglucosan bodies: Lafora disease.
    Minassian BA
    Adv Neurol; 2002; 89():199-210. PubMed ID: 11968446
    [No Abstract]   [Full Text] [Related]  

  • 14. Inhibiting glycogen synthesis prevents Lafora disease in a mouse model.
    Pederson BA; Turnbull J; Epp JR; Weaver SA; Zhao X; Pencea N; Roach PJ; Frankland PW; Ackerley CA; Minassian BA
    Ann Neurol; 2013 Aug; 74(2):297-300. PubMed ID: 23913475
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Laforin, the dual-phosphatase responsible for Lafora disease, interacts with R5 (PTG), a regulatory subunit of protein phosphatase-1 that enhances glycogen accumulation.
    Fernández-Sánchez ME; Criado-García O; Heath KE; García-Fojeda B; Medraño-Fernández I; Gomez-Garre P; Sanz P; Serratosa JM; Rodríguez de Córdoba S
    Hum Mol Genet; 2003 Dec; 12(23):3161-71. PubMed ID: 14532330
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An inducible glycogen synthase-1 knockout halts but does not reverse Lafora disease progression in mice.
    Nitschke S; Chown EE; Zhao X; Gabrielian S; Petković S; Guisso DR; Perri AM; Wang P; Ahonen S; Nitschke F; Minassian BA
    J Biol Chem; 2021; 296():100150. PubMed ID: 33277363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Astrocytic glycogen accumulation drives the pathophysiology of neurodegeneration in Lafora disease.
    Duran J; Hervera A; Markussen KH; Varea O; López-Soldado I; Sun RC; Del Río JA; Gentry MS; Guinovart JJ
    Brain; 2021 Sep; 144(8):2349-2360. PubMed ID: 33822008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A PTG variant contributes to a milder phenotype in Lafora disease.
    Guerrero R; Vernia S; Sanz R; Abreu-Rodríguez I; Almaraz C; García-Hoyos M; Michelucci R; Tassinari CA; Riguzzi P; Nobile C; Sanz P; Serratosa JM; Gómez-Garre P
    PLoS One; 2011; 6(6):e21294. PubMed ID: 21738631
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ppp1r3d deficiency preferentially inhibits neuronal and cardiac Lafora body formation in a mouse model of the fatal epilepsy Lafora disease.
    Israelian L; Nitschke S; Wang P; Zhao X; Perri AM; Lee JPY; Verhalen B; Nitschke F; Minassian BA
    J Neurochem; 2021 Jun; 157(6):1897-1910. PubMed ID: 32892347
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glycogen accumulation underlies neurodegeneration and autophagy impairment in Lafora disease.
    Duran J; Gruart A; García-Rocha M; Delgado-García JM; Guinovart JJ
    Hum Mol Genet; 2014 Jun; 23(12):3147-56. PubMed ID: 24452334
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.